181365-26-4 Usage
General Description
1-(tert-butoxycarbonyl)indole-3-boronic acid is a chemical compound used in organic synthesis and pharmaceutical research. It is a boronic acid derivative that contains an indole ring, which gives it unique reactivity and potential pharmacological properties. The tert-butoxycarbonyl group serves as a protective group, which can be selectively removed under certain conditions, allowing for further functionalization of the molecule. 1-(TERT-BUTOXYCARBONYL)INDOLE-3-BORONIC ACID is commonly used as a building block in the synthesis of biologically active molecules and as a tool in the development of new drugs and agrochemicals. Its versatile reactivity and potential biological activity make it a valuable and important chemical in the field of medicinal chemistry and drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 181365-26-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,3,6 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 181365-26:
(8*1)+(7*8)+(6*1)+(5*3)+(4*6)+(3*5)+(2*2)+(1*6)=134
134 % 10 = 4
So 181365-26-4 is a valid CAS Registry Number.
181365-26-4Relevant articles and documents
Pyrimidine derivatives Anaplastic lymphoma kinase inhibitors
-
, (2017/07/23)
The invention belongs to the field of a medical technology and specifically relates to a pyrimidine derivative type anaplastic lymphoma kinase inhibitor as shown in the general formula (I) or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate, wherein R1, R2, R3, R4, R5 and A ring are as defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutic preparation and a pharmaceutical composition containing the compounds and an application of the compound or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate in the preparation of medicines for treating and/or preventing diseases related to anaplastic lymphoma kinase-mediated cancer.
